These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29476514)

  • 1. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
    Bassani-Sternberg M
    Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Immunopeptidomics We Need a Sniper Instead of a Shotgun.
    Faridi P; Purcell AW; Croft NP
    Proteomics; 2018 Jun; 18(12):e1700464. PubMed ID: 29377634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopeptidomics Special Issue.
    Ternette N; Purcell AW
    Proteomics; 2018 Jun; 18(12):e1800145. PubMed ID: 29949244
    [No Abstract]   [Full Text] [Related]  

  • 4. Mass spectrometry-based antigen discovery for cancer immunotherapy.
    Bassani-Sternberg M; Coukos G
    Curr Opin Immunol; 2016 Aug; 41():9-17. PubMed ID: 27155075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Throughput, Fast, and Sensitive Immunopeptidomics Sample Processing for Mass Spectrometry.
    Marino F; Chong C; Michaux J; Bassani-Sternberg M
    Methods Mol Biol; 2019; 1913():67-79. PubMed ID: 30666599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
    Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
    Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOF
    Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
    Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Tools for the Identification and Interpretation of Sequence Motifs in Immunopeptidomes.
    Alvarez B; Barra C; Nielsen M; Andreatta M
    Proteomics; 2018 Jun; 18(12):e1700252. PubMed ID: 29327813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery.
    Zhang B; Bassani-Sternberg M
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the Cryptic HLA-I Immunopeptidome.
    Erhard F; Dölken L; Schilling B; Schlosser A
    Cancer Immunol Res; 2020 Aug; 8(8):1018-1026. PubMed ID: 32561536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal Information About an Immuno-Peptidomics Experiment (MIAIPE).
    Lill JR; van Veelen PA; Tenzer S; Admon A; Caron E; Elias JE; Heck AJR; Marcilla M; Marino F; Müller M; Peters B; Purcell A; Sette A; Sturm T; Ternette N; Vizcaíno JA; Bassani-Sternberg M
    Proteomics; 2018 Jun; 18(12):e1800110. PubMed ID: 29791771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
    Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
    Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of HLA class I-binding peptides derived from unique cancer-associated proteins by mass spectrometric analysis.
    Kamata Y; Kuhara A; Iwamoto T; Hayashi K; Koido S; Kimura T; Egawa S; Homma S
    Anticancer Res; 2013 May; 33(5):1853-9. PubMed ID: 23645730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification and Identification of Naturally Presented MHC Class I and II Ligands.
    Nelde A; Kowalewski DJ; Stevanović S
    Methods Mol Biol; 2019; 1988():123-136. PubMed ID: 31147937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis.
    Sirois I; Isabelle M; Duquette JD; Saab F; Caron E
    J Vis Exp; 2021 Oct; (176):. PubMed ID: 34723952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry.
    Kalaora S; Samuels Y
    Methods Mol Biol; 2019; 1884():203-214. PubMed ID: 30465205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.